I have read with interest the paper by Dr. Bari et al. reporting on the use of livers from hepatitis C virus (HCV) antibody–positive, nucleic acid test–negative (nonviremic) donors into HCV negative recipients and would like to congratulate the authors for such important contribution.1 I would like to emphasize that, due to increasing mortality on the waitlist and excellent antiviral treatment, the transplant community should also use livers from HCV viremic donors for selected HCV negative recipients.